This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wide Field Looking to Trim Weight

Few companies are placing all their bets on the obesity market, but several biotechs are working on diseases that can be caused by being overweight, such as diabetes and cancer.

For instance, OSI Parmaceuticals (OSIP), best known for marketing the cancer drug Tarceva with Genentech (DNA), has a subsidiary focused on obesity and diabetes called Prosidion. The division is developing drugs that target the high blood-sugar levels that contribute to the diseases.

Another company, Myriad Genetics (MYGN - Get Report), has discovered a gene linked to an overeating disorder called hyperphagia and early onset obesity. The latter dramatically increases one's risk of developing Type 2 diabetes, a condition that's growing in proportion with cases of obesity.

Nastech Pharmaceutical (NSTK) has jumped into the field with its recent acquisition of certain patents from Cedars-Sinai Medical Center to support an investigational nasal spray for obesity.

The spray contains a hormone that regulates appetite control, and it's currently in three early-stage trials on its safety and tolerability. If it's ultimately successful, the drug will be marketed by Merck (MRK).

Meanwhile, Icoria (ICOR), a company with a $10 million market capitalization that trades on the over-the-counter Bulletin Board, has also heard the calling of the obesity market.

Originally focused on agriculture under the name Paradigm Genetics, Icoria sold off its plant research unit to focus on developing obesity and diabetes treatments. The company has agreed to be acquired by Clinical Data (CLDA), a blood products and services company.

Wittes says other companies may eventually broaden the field, perhaps makers of neurostimulation devices such as Cyberonics (CYBX) and Boston Scientific's (BSX) Advanced Bionics, though neither company has made any announcements to that effect. At any rate, as with ordinary weight-loss techniques, only time will tell if the new crop of obesity fighters can keep the weight off.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMDC $0.00 0.00%
MDT $79.09 -0.44%
MYGN $34.52 -4.60%
STJ $75.61 -0.32%
AAPL $94.94 -0.25%


Chart of I:DJI
DOW 17,693.45 -57.46 -0.32%
S&P 500 2,052.60 -10.77 -0.52%
NASDAQ 4,739.23 -23.9940 -0.50%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs